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Abstract
Background: There is a need to identify individuals with COPD at risk for disease progression and mortality. Lung
tissue remodeling is associated with the release of extracellular matrix (ECM) fragments into the peripheral
circulation. We hypothesized that ECM remodeling was associated with mortality in COPD and measured neo-
epitopes originating from ECM proteins associated with lung tissue remodeling.
Methods: Biomarkers of ECM remodeling were assessed in a subpopulation (n = 1000) of the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) cohort. Validated immunoassays measuring
serological neo-epitopes produced by proteolytic cleavage associated with degradation of collagen type I, III, IV,
and VI, elastin, and biglycan, and formation of collagen type VI as well as fibrinogen and C-reactive protein were
used. Multivariate models were used to assess the prognostic value of these biomarkers.
Results: Thirty subjects (3.0 %) died during follow-up. Non-survivors were older, had reduced exercise capacity,
increased dyspnea score, and included fewer current smokers. All collagen biomarkers were significantly elevated in
non-survivors compared to survivors. Mortality risk was significantly increased for subjects with collagen remodeling
biomarkers in the upper quartile, especially for the degradation fragment of collagen type IV C6M (hazard ratio 6.6
[95 % confidence interval 2.9-15.2], P < 0.0001) after adjusting for relevant confounders.
Conclusions: Serological biomarkers of collagen remodeling were strongly associated with mortality in subjects
with COPD indicating that assessment of tissue turnover in the parenchyma and small airways may be useful in the
prognosis of COPD.
Trial registration: NCT00292552, GSK Study No. SCO104960.
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Background
Chronic obstructive pulmonary disease (COPD) is a
heterogeneous disease characterized by progressive
airflow limitation and a chronic inflammatory response
of the lungs. It is a major cause of morbidity and mortal-
ity and is estimated to be the third leading cause of
death worldwide [1]. Poor lung function, lung function
decline [2], low body mass index (BMI) [2], a high level
of dyspnea [3], frequent exacerbations [4], and low levels
of physical activity [5] have all been identified as predic-
tors of mortality in individuals with COPD. Using multi-
dimensional risk scores [6] or adding markers of
systemic inflammation [7] adds to the predictive value,
exceeding the prognostic value of lung function alone.
The recent statement from the American Thoracic
Society and the European Respiratory Society on re-
search questions in COPD encourages the identification
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of surrogate markers of patient-centered outcomes such
as quality of life and mortality [8]. Being able to further
improve prediction of mortality would aid in the selec-
tion of patients for specific interventions and clinical
trials and would ultimately improve personalized
healthcare.
The chronic inflammatory response in the airways of
individuals with COPD is associated with increased
numbers of inflammatory cells and fibroblasts and the
up-regulation of proteases such as matrix metallopro-
teinases (MMPs) resulting in fibrosis of small airways
and destruction of the parenchyma [9]. The altered
microenvironment affects the composition of the
extracellular matrix (ECM), mainly comprised of colla-
gens and elastin [10]. The two main extracellular
compartments of the lungs are the basement membrane
and the interstitial matrix (Fig. 1). The main constituent
of the basement membrane is collagen type IV, whereas
the interstitial matrix is rich in collagens type I and III
and elastin. The chronic inflammatory process in the
lungs of individuals with COPD induces the remodeling
of the ECM, which includes both degradation of old pro-
teins and synthesis of new ones and occurs in both small
airways and alveolar walls. This results in the release of
protein fragments or neo-epitopes into the systemic
circulation where they can be assessed as biomarkers of
lung ECM remodeling (Fig. 1). C1M, C3M, C3A, and
C6M are biomarkers of collagen type I, III and VI
degradation, respectively, whereas Pro-C6 assesses the
C5 domain of collagen type VI believed to be released
Fig. 1 Extracellular matrix composition in healthy and COPD lungs. In healthy lungs, the epithelial cells create a tight barrier thereby blocking
entry of foreign particles from the inhaled air to the tissue. This is further enforced by the underlying basement membrane (BM) which mainly
consists of collagen type IV. The interstitial matrix (IM) is below the BM and consists mainly of fibrillar collagens and elastin. In COPD, the
continuous epithelial layer is disrupted and the underlying BM is exposed. The inflammatory response to repetitive tissue injury results in up-regulation
of proteases and disruption of the BM, allowing for injury to the underlying IM. In response to this, fibroblasts are activated and converted to pro-
fibrotic myofibroblasts that secrete collagens which accumulate in the IM of the airway wall. Both collagens and elastin undergoes
proteolytic degradation in the airway and alveolar walls. The processes of synthesis and degradation release extracellular matrix (ECM)
fragments which may enter the bloodstream from where they can be assessed as biomarkers of ECM remodeling
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during protein maturation [11–14]. C4M is a bio-
marker of collagen type IV degradation mediated by
MMPs and thus assesses basement membrane
destruction [15]. EL-NE and ELM7 are biomarkers of
neutrophil elastase- and MMP-7-mediated degradation
of elastin, a protein crucial for the elastic recoil of
the lungs [16, 17]. The proteoglycan biglycan is a key
player in the assembly of collagen fibrils and its deg-
radation by MMPs can be assessed by the biomarker
BGM [18]. The biomarker CRPM assesses the local
inflammation by measuring MMP-mediated degrad-
ation of C-reactive protein (CRP) [19].
As excessive ECM remodeling resulting from repeti-
tive injury is associated with COPD [20], we hypothe-
sized that measuring serological biomarkers of ECM
protein remodeling would be helpful in predicting all-
cause mortality in individuals with COPD. We investi-
gated this by assessing biomarkers of ECM degradation
and formation in a subpopulation of the Evaluation of
COPD Longitudinally to Identify Predictive Surrogate
End-points (ECLIPSE) cohort. We included analyses of
the previously studied CRP and fibrinogen [7] for
comparison of prognostic performance.
Methods
Study design
The study design of ECLIPSE (clinicaltrials.gov identifier
NCT00292552; GSK study code SCO104960) has been
described in detail previously [21, 22]. Briefly, ECLIPSE
is an observational, longitudinal study where partici-
pants were evaluated at baseline and at months three
and six, and subsequently every six months for three
years. For these analyses, we used clinical and bio-
marker data obtained at baseline, month six and year
one. Death was determined up to day 1060 of the
study. Cause of death was not available for the present
analyses. ECLIPSE complies with the Declaration of
Helsinki and Good Clinical Practice Guidelines, and has
been approved by the ethics committees of the participat-
ing centers. All participants provided written informed
consent before the performance of any study-related
assessments.
Population
The full ECLIPSE study included 2164 subjects with
COPD based on a post-bronchodilator forced expiratory
volume in one second (FEV1) < 80 % of the reference
value, FEV1/forced vital capacity (FVC) ≤ 0.7, and a smok-
ing history of greater than or equal to 10 pack-years [21].
The current analyses were performed on a sub-population
of 1000 COPD subjects of the ECLIPSE cohort composed
of the 500 subjects that progressed the most and the 500
subjects that progressed the least in terms of FEV1 decline
over the three year study period. Participants were re-
cruited from the outpatient clinics of the participating
centers. Significant emphysema was defined as low attenu-
ation area at −950 Hounsfield Units (%LAA) ≥ 10 % on
chest computed tomography (CT) scans. Non-
emphysematous COPD was defined as %LAA < 5 %.
Measurements of serological biomarkers
Whole blood was collected by venipuncture into vacutai-
ner tubes from participants in the fasting state. Serum
was prepared by allowing the blood to clot for 30 min at
room temperature followed by centrifugation at 1500 g
for 10–15 min. Plasma was obtained by centrifugation of
vacutainer tubes at 2000 g for 10–15 min. Serum and
plasma were stored at −80 °C until analyzed and did not
undergo any freeze/thaw cycles prior to measurements of
the current biomarkers. C1M, BGM, EL-NE, and Pro-C6
were measured in month six serum samples, while C3A,
C3M, C4M, C6M, ELM7, and CRPM were measured in
year one plasma (heparin anticoagulant) samples. Details
of these biomarkers are presented in Table 1. Prior to this
Table 1 Biomarker specifications
Biomarker Specifications Measure References
BGM Biglycan degraded by MMPs IM remodeling [18]
C1M Collagen type I degraded by MMPs IM remodeling [11]
C3A Collagen type III degraded by ADAMTS IM remodeling Unpublisheda
C3M Collagen type III degraded by MMP IM remodeling [12]
C4M Collagen type IV degraded by MMPs BM remodeling [15]
C6M Collagen type VI degraded by MMPs IM remodeling [13]
CRPM CRP degraded by MMPs Local chronic inflammation [19]
ELM7 Elastin degraded by MMP-7 IM remodeling [17]
EL-NE Elastin degraded by neutrophil elastase IM remodeling [16]
Pro-C6 Collagen type VI C5 domain (released) IM remodeling [14]
MMP matrix metalloproteinase, ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs, IM interstitial matrix, BM basement membrane, CRP
C-reactive protein
aThe C3A assay was validated following a standard protocol as described in [11]
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study, fibrinogen and CRP (high-sensitivity method) were
measured in year one plasma (ethylenediaminetetraacetic
acid anticoagulant) samples as described previously [7].
All biomarkers were measured by validated competitive
ELISAs utilizing monoclonal antibodies targeting specific
neo-epitopes (Nordic Bioscience, Herlev, Denmark)
[11–19] and measurements were performed in a
blinded manner according to the manufacturer’s
instructions. Analytes detected by these assays are
stable in serum/plasma samples that have undergone
at least four freeze/thaw cycles [11–19].
Statistical analysis
Survivor and non-survivor characteristics were com-
pared using student’s t-test, chi-squared test, or Mann–
Whitney U test as appropriate. Serological biomarker
data were logarithmically transformed to obtain normal-
ity and are shown as geometric mean with standard
error of mean (SEM). Biomarker levels were compared
between groups with student’s t-test. Cox proportional
hazards analyses were used to assess the prognostic
value of each biomarker for all-cause mortality for a one
standard deviation increase in biomarker and comparing
the upper and lower biomarker quartiles. The risk of
death was assessed using crude analyses and analyses
adjusted for age, BODE index (added as categorical vari-
able), and number of exacerbations in the year prior to
baseline measurements. The discriminative power of
each serological biomarker, the clinical model (age,
BODE, and previous exacerbations), and the clinical
model with additions of one or more serological bio-
marker were assessed by receiver operating curve (ROC)
analyses. Area under the ROC curve (AUC) for the clin-
ical model was compared with that of the clinical model
with added serological biomarkers by the method of
Delong et al. 1988 [23]. All tests performed (SAS version
9.3, SAS Institute Inc., Cary, NC, USA; MedCalc version
14.8.1, MedCalc Software bvba, Ostend, Belgium)
were two-sided at the 0.05 level of significance, and
all P values are nominal as no adjustments were
made for multiple comparisons.
Results
Basic demographics
Of the 1000 subjects included, 985 (99 %) were Caucasians,
363 (36 %) were female, and mean age was 63 (SD 7) years.
BGM, EL-NE, and ProC6 were significantly related to gen-
der with mean levels in male vs. female of 46.09 (95 % CI
44.52–47.70) ng/mL vs. 42.04 (95 % CI 40.29–43.88) ng/
mL (p = 0.0013), 8.23 (95 % CI 7.77–8.71) ng/mL vs. 7.15
(95 % CI 6.67–7.67) ng/mL (p = 0.0029), and 6.51 (95 % CI
6.35–6.67) ng/mL vs. 6.25 (95 % CI 6.06–6.45) ng/mL (p =
0.048), respectively.
Thirty subjects (3.0 %) died during the follow-up
period of a minimum of two years from time of
blood sampling. Table 2 shows the baseline character-
istics of survivors and non-survivors. Non-survivors
were significantly older, reported more dyspnoea,
lower fatigue scores, had reduced 6MWD, and fewer
subjects were current smokers. Severity of airflow
limitation, comorbidity profile, presence of emphy-
sema on high-resolution computed tomography scan,
BODE index, number of exacerbations, and medica-
tions were not significantly different between survi-
vors and non-survivors.
ECM remodeling related to emphysema
At year one, 624 subjects presented with significant em-
physema, defined as a %LAA ≥10 %, while 147 subjects
showed no signs of emphysema on chest CT scan,
defined as %LAA <5 %. Mean %LAA for subjects with
and without emphysema was 22.8 % (SD 9.9) and 3.1 %
(SD 1.3), respectively. CRPM was the only biomarker
that differed significantly between emphysematous and
non-emphysematous COPD, with levels of 9.37 (95 % CI
9.09–9.65) ng/mL and 10.11 (95 % CI 9.43–10.84) ng/
mL, respectively (p = 0.032).
Of the subjects with significant emphysema, 550 had
data available at year three and had a mean change in
%LAA from year one of +5.5 % (SD 22.3). Subjects with
increased %LAA (emphysema progressors), had signifi-
cantly lower levels of C1M, EL-NE, and ProC6 than
those with a negative or no change in %LAA (emphysema
non-progressors) (C1M: 68.85 ng/mL (95 % CI 64.74–
73.21) vs. 77.67 ng/mL (95 % CI 71.31–84.61), p = 0.022;
EL-NE: 7.34 ng/mL (95 % CI 6.81–7.91) vs. 8.41 ng/mL
(95 % CI 7.64–9.25), p = 0.028; ProC6: 6.16 ng/mL
(95 % CI 5.98–6.34) vs. 6.52 ng/mL (95 % CI 6.25–
6.81), p = 0.032).
ECM remodeling related to mortality
Eight of the ten serological biomarkers of ECM remodel-
ing (C1M, C3A, C3M, C4M, C6M, ProC6, ELM7, and
CRPM, but not EL-NE and BGM) were significantly ele-
vated in subjects who died compared to survivors (Fig. 2).
Plasma CRP, but not fibrinogen, was also significantly
elevated in non-survivors (Fig. 2).
Figure 3 shows the crude and adjusted (age, BODE,
and previous exacerbations) Cox proportional hazards
ratios for death within the follow-up period. The ECM
remodeling biomarker C6M was most prognostic for all-
cause mortality with crude and confounder-adjusted
hazard ratios of 6.8 (95 % CI 3.2–14.5, P < 0.0001) and
6.6 (95 % CI 2.9–15.2, P < 0.0001), respectively, for sub-
jects belonging to the upper vs. lower biomarker quar-
tile. CRP performed equally well with hazard ratios of 7.7
(95 % CI 3.4–17.4, P < 0.0001) and 7.0 (95 % CI 2.9–16.8,
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P < 0.0001), respectively. C1M, C3A, C3M, C4M, CRPM,
Pro-C6, and fibrinogen were also prognostic for mortality
in both crude and adjusted analyses. Further adjustment
for variables that were significantly different between
survivors and non-survivors (Table 2) resulted in similar
hazard ratios (data not shown).
Table 2 Subject characteristics at baseline
Survivors Non-survivors P value
(n = 970) (n = 30)
Demographics
Age (yrs)* 63 ± 7 68 ± 6 <0.0001
Female gendera 352 (36) 11 (37) 0.97
BMI (kg/m2)* 26.8 ± 5.8 27.3 ± 7.8 0.78
Current smoker (%)a 366 (38) 3 (10) 0.004
Pack years (yrs)* 47 ± 25 56 ± 42 0.27
Clinical variables
FEV1 (L)* 1.42 ± 0.51 1.27 ± 0.43 0.11
FEV1 (% predicted)* 51 ± 15 48 ± 13 0.44
GOLD Stageb
II 480 (49) 14 (47) 0.93
III 392 (40) 14 (47)
IV 98 (10) 2 (7)
Number of previous exacerbationsb
0 531 (55) 20 (67) 0.29
1 239 (25) 5 (17)
2 116 (12) 2 (7)
> 2 84 (9) 3 (10)
6MWD (meters)* 386 ± 119 335 ± 105 0.02
mMRC dyspnoea score; median (Q1; Q3) b 1 (1;2) 2 (1;3) 0.02
%LAA (%)* 16.3 ± 11.3 17.4 ± 10.5 0.61
BODE index; median (Q1; Q3) b 3 (1;4) 3.5 (2;5) 0.06
SGRQ total score* 46 ± 18 50 ± 20 0.29
FACIT fatigue score* 36 ± 10 31 ± 12 0.01
Comorbiditiesa
Cardiovascular history 304 (31) 12 (40) 0.42
Hypertension 381 (39) 14 (47) 0.53
Asthma history 225 (23) 8 (27) 0.82
Diabetes type II 82 (8) 3 (10) 0.97
Osteoarthritis 125 (13) 3 (10) 0.85
Osteoporosis 121 (12) 6 (20) 0.35
Rheumatoid arthritis 29 (3) 0 (0) 0.68
Inflammatory bowel disorder 48 (5) 1 (3) 0.98
Interventionsa
Inhaled corticosteroids 140 (14) 3 (10) 0.68
Systemic corticosteroids 8 (0.8) 0 (0) 0.59
Statins 237 (24) 6 (20) 0.73
Data are shown as mean ± SD or n (%) at baseline unless otherwise stated
BMI body mass index, FEV1 postbronchodilator forced expiratory volume in one second, GOLD global initiative for chronic obstructive lung disease, 6MWD 6-min
walk distance, mMRC modified Medical Research Council dyspnoea scale, %LAA low attenuation area at −950 Hounsfield Units, BODE BMI, airflow obstruction,
dyspnea and exercise capacity index, SGRQ St George’s respiratory questionnaire, FACIT functional assessment of chronic illness therapy
Statistical significance was determined using student’s t-test (*), chi-squared test (a), or Mann–Whitney U test (b)
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Kaplan-Meier survival curves for the biomarkers with
crude hazard ratios above 5.0 (C3A, C3M, C6M, Pro-C6,
CRP) are shown in Fig. 4. For all five biomarkers, being
in the upper quartile was associated with an increased
number of deaths. In the upper quartile of C6M, 16 out
of 249 (6.4 %) subjects died, while only 3 of 249 (1.3 %)
died in the lower quartile. For Pro-C6, the similar num-
bers were 17 out of 235 (7.2 %) and 3 out of 223 (1.4 %),
respectively. By selecting subjects belonging to the upper
quartile of both C6M and Pro-C6, we identified 10 sub-
jects (11.1 %) that died during the follow-up period out
of the 90 subjects that were in the upper quartile for
C6M and Pro-C6.
The discriminatory power for predicting death of the
serological biomarkers alone and a clinical model with
added serological biomarkers was assessed by ROC ana-
lyses (Table 3). The AUC for the clinical model (includ-
ing age, BODE, and previous exacerbations) was 0.750
(95 % CI 0.721–0.778) and the addition of one or more
biomarkers to this model increased the AUC to 0.871
(95 % CI 0.846–0.893, P = 0.0004) for the addition of
C6M, Pro-C6, and CRP.
Discussion
We have shown for the first time that elevated levels
of serological biomarkers of ECM remodeling were
Fig. 2 Biomarker levels in survivors versus non-survivors. Biomarker levels were assessed at month six (BGM, C1M, EL-NE, Pro-C6) or year
one (C3A, C3M, C4M, C6M, CRPM, ELM7, CRP, fibrinogen) in survivors (n = 970) and non-survivors (n = 30). All biomarkers, with the exception of BGM,
EL-NE, and fibrinogen, were significantly elevated in non-survivors compared to survivors. Data are shown as geometric mean ± SEM.
Statistical significance was determined using student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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associated with increased mortality in subjects with
COPD. Several novel biomarkers of collagen degrad-
ation were significant predictors of mortality within
two years of follow-up in a subpopulation of the
ECLIPSE cohort. Results for biomarkers of ECM
remodeling (collagen type I (C1M), III (C3A, C3M),
IV (C4M), and VI (C6M) degradation and collagen
type VI formation (Pro-C6)), strongly suggest that
remodeling of the interstitial collagens is of high
importance in COPD.
In individuals with COPD, the remodeling of the lung
ECM is altered as a consequence of the inflammatory
process and the delicate balance between protein forma-
tion and degradation is shifted, affecting both the struc-
ture and function of the tissue [24]. In both alveolar and
small airway walls of individuals with COPD, fibrillar
Fig. 3 Cox proportional hazards ratios for death. Hazard ratios (HR) for death are shown per one standard deviation increase in biomarker (a + b)
and for subjects in the upper vs. lower quartile (c + d). Cox proportional HR with 95 % confidence intervals are shown for crude analyses (a + c)
and analyses adjusted for age, BODE, and previous exacerbations (b + d). All biomarkers, with the exception of BGM, ELM7, and EL-NE, were
significantly related to mortality outcome in both crude and adjusted analyses. Statistical significant hazard ratios are indicated as
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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collagen content, as well as collagen type VI, has been
found to be increased while elastin content was de-
creased, compared to controls [25, 26]. A preliminary
study assessing biomarkers of ECM turnover in ten sub-
jects with mild COPD found elevated levels of collagen
neo-epitopes as compared to healthy controls, indicating
an excessive ECM remodeling already in mild COPD
[27]. Elevated levels of biomarkers of ECM degradation
during exacerbations of COPD as compared to the stable
state furthermore indicate a relation of the rate of ECM
turnover to disease activity [28, 29]. However, these
smaller studies lack long-term follow-up.
Most likely, initial injury to the airways and lung par-
enchyma disrupts the continuous epithelial cell layer
and exposes the underlying basement membrane, which
mainly consists of collagen type IV. The subsequent
destruction of the basement membrane by MMPs, up-
regulated in response to injury, release fragments of
collagen type IV (C4M) to the circulation. Deeper and
chronic tissue damage expose the underlying interstitial
matrix, consisting mainly of collagen type I and III, to
tissue remodeling, resulting in the destruction of the
interstitial matrix and the release of fragments of colla-
gen type I (C1M), III (C3A and C3M), and VI (C6M).
The repetitive tissue injury is believed to increase ECM
remodeling rate and shift the balance of synthesis and
degradation, favoring collagen deposition in small airway
walls (fibrosis) and destruction of collagens and elastin
in alveolar walls (emphysema) [10] (Fig. 1). By measur-
ing MMP-mediated protein degradation, the local
inflammatory process is included in the assessments.
This is true for the collagen, elastin and CRP biomarkers
assessed here. The alterations in lung ECM in relation to
COPD lead to the release of specific protein neo-
epitopes to the systemic circulation, thus allowing for
the assessment of tissue remodeling by use of serological
biomarkers [30] (Fig. 1).
In the present study, we found that biomarkers of the
structural changes occurring in both the basement
membrane and the interstitial matrix of the lungs were
related to mortality in individuals with COPD. In the lar-
gest biomarker study in idiopathic pulmonary fibrosis to
date, remodeling of the interstitial matrix and proteolytic
degradation of CRP was also shown to be related to dis-
ease progression and mortality [31]. Consequently, the
remodeling of the interstitial matrix is of paramount im-
portance for both lung diseases encompassing fibrotic
lesions. Our data indicate that collagen remodeling result-
ing in destruction of alveolar walls and both destruction
and thickening of the small airway walls may be assessed
by serological biomarkers, the levels of which are associ-
ated with mortality in COPD. Interestingly, we found no
Fig. 4 Kaplan-Meier survival curves for biomarker quartiles. Kaplan-Meier survival curves are shown for the biomarkers with crude hazard ratios for
quartile 4 vs. 1 above 5. The relationship of biomarker quartiles with survival time from blood sampling are shown for plasma C3A (year one),
plasma C3M (year one), plasma C6M (year one), serum ProC6 (month six), and plasma CRP (year one). Subjects in the upper biomarker quartiles
(Q4) showed a higher number of deaths within the study period than the lower quartiles
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association of mortality with markers of elastin degrad-
ation, although an association to all-cause mortality has
previously been reported for desmosine, another marker
of elastin degradation [32]. This difference may be due to
the neo-epitope specificity of the present biomarkers,
which require specific protease activity in a specific
location, or a difference in clearing from the blood for dif-
ferent elastin fragments. Interestingly, especially the re-
modeling of collagen type VI was shown to be associated
with mortality in COPD in the current study. Collagen
type VI is a unique beaded filament type of collagen found
in the interstitial matrix near the basement membrane. It
forms a microfibrillar network believed to anchor base-
ment membranes, collagen fibers and cells to the connect-
ive tissue [33–35]. Furthermore, it may act as an early
sensor of the injury/repair response as well as a regulator
of fibrogenesis by modulating cell-cell interactions, stimu-
lating proliferation of mesenchymal cells, and preventing
cell apoptosis [36, 37]. The expression of collagen type VI
has been found increased in fibrotic lungs [38] and its C5
domain, also known as endotrophin, has been shown to
trigger adipose tissue fibrosis [39]. These functions point
to an important role for collagen type VI in the
development of fibrosis and may indicate a crucial func-
tion of this structural and functionally important collagen
type in COPD as well.
Previous studies of serological biomarkers for the pre-
diction of outcomes in individuals with COPD have
mainly focused on the systemic inflammatory response
by evaluating biomarkers such as interleukin-6, CRP and
fibrinogen. However, plasma CRP levels shows a wide
variability in individuals with stable COPD [40], making
it less suitable as a prognostic biomarker for individual
patients. Several of the biomarkers assessed here have
previously been found to have low variability over a six
months period in individuals with idiopathic pulmonary
fibrosis [31]. Neo-epitopes released in relation to ECM
remodeling are the “end products” of the local tissue
inflammation and repair processes in the lungs [41],
which might explain the relatively stable measurements
of these biomarkers over time. However, ECM neo-
epitopes are not exclusively released from lung tissue. A
continuous low rate remodeling upholds integrity of all
tissues in the body, giving rise to a steady background
neo-epitope level in the systemic circulation. Chronic in-
flammation and fibrosis trigger a significant increase in
tissue remodeling resulting in the release of pathology-
related neo-epitopes above normal background levels. By
assessing neo-epitopes as opposed to full length pro-
teins, the signal-to-noise ratio may be improved by util-
izing post-translational modifications, in this case
proteolytic cleavage, that are associated with pathology
[42, 43]. As with many systemic biomarkers, these neo-
epitopes may originate from other organ systems than
the lung, especially in relation to significant comorbidi-
ties that may affect tissue turnover. However, as COPD
may be viewed as a systemic disease, the possible contri-
bution from other affected organs may provide an
assessment of the overall burden of disease.
It is intriguing that emphysema seems to be associated
with lower levels of ECM remodeling while mortality is
associated with higher levels. These results indicate that
different pathological processes are related to distinct
processing of the ECM leading to different levels of neo-
epitopes. Acute exacerbations of COPD are generally as-
sociated with higher levels of remodeling [28], and
individuals with lung cancer also show accelerated
remodeling [44]. Emphysema seems to represent a
different pathological process leading to a different pat-
tern of remodeling. Clearly, more research is needed in
this area to understand the specific mechanisms involved
in pathological tissue turnover.
The recent qualification by the United States Food and
Drug Administration of plasma fibrinogen as a drug
development tool for enrichment of clinical trials in
COPD, using exacerbations or all-cause mortality as
endpoints [45–47], has helped pave the way for the use
Table 3 Discriminatory power for the prognosis of death
AUC (95 % CI) P value
Serological biomarkers
C6M 0.724 (0.695–0.752) -
Pro-C6 0.722 (0.692–0.751) -
CRP 0.719 (0.689–0.747) -
C6M + Pro-C6 0.796 (0.769–0.822) -
C6M + CRP 0.727 (0.697–0.755) -
Pro-C6 + CRP 0.775 (0.746–0.802) -
C6M + Pro-C6 + CRP 0.791 (0.762–0.818) -
Clinical models
Age + BODE + Previous exacerbations 0.750 (0.721–0.778)
+ C3M 0.803 (0.776–0.829) 0.084
+ CRPM 0.807 (0.780–0.832) 0.044
+ C6M 0.813 (0.786–0.837) 0.038
+ Pro-C6 0.826 (0.799–0.851) 0.071
+ CRP 0.811 (0.783–0.836) 0.046
+ C6M + Pro-C6 0.867 (0.843–0.889) 0.001
+ C6M + CRP 0.817 (0.790–0.842) 0.023
+ C6M + CRPM 0.818 (0.791–0.842) 0.036
+ Pro-C6 + CRP 0.863 (0.837–0.886) 0.001
+ Pro-C6 + CRPM 0.864 (0.840–0.886) 0.003
+ C6M + Pro-C6 + CRP 0.871 (0.846–0.893) 0.0004
+ C6M + Pro-C6 + CRPM 0.871 (0.847–0.893) 0.001
Shown are the single biomarkers with an area under the ROC curve (AUC)
>0.700 and models with AUC >0.800. P values compare the AUC of the clinical
model alone to the clinical model with added biomarker(s)
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of validated biomarkers in clinical trials of COPD. Inter-
estingly, in the present study several of the novel
biomarkers, as well as CRP, performed better than fi-
brinogen for the prediction of all-cause mortality. The
association of plasma fibrinogen with COPD has been
seen in several studies [48, 49]. Although plasma fibrino-
gen is qualified as a biomarker for mortality in COPD, a
recent review by Sin et al. concludes that none of the
biomarkers investigated thus far have sufficient perform-
ance characteristics or specificity to be a clinically useful
biomarker in COPD [50]. The ideal biomarker is stable
over time and is related to the pathological process. As
the COPD population is very heterogeneous, it seems
likely that biomarkers reflecting different pathological
processes may be needed for monitoring progression in
different subtypes of COPD. Thus, the need of tools to
assess disease activity is still a major limitation to the
development of novel therapeutic approaches in
COPD, as well as in the management and prognosis
of disease [30, 50]. Biomarkers with these qualities
would aid personalized health care and could have the
potential to improve patient care tremendously [30].
Limitations to this study include the low number of
deceased subjects, reducing statistical power. In spite of
this, we found significant associations with mortality.
The individuals included in this study are a subpopula-
tion of the full ECLIPSE study comprising the study par-
ticipants that progress the least and the most in terms of
FEV1 decline during the study period. This is not the
optimal population to study mortality in, and may
explain the low number of events in this population.
Furthermore, the present results need to be confirmed
in an independent cohort to determine if the associa-
tions are applicable to the general COPD population.
Conclusions
In conclusion, with this study we have demonstrated
that mortality in individuals with COPD is associated
with elevated levels of serological biomarkers of collagen
remodeling. These biomarkers were prognostic for all-
cause mortality, suggesting that a high remodeling rate
is related to increased risk of mortality. The increased
degradation of collagens found in the interstitial matrix
of the lungs, indicate that ECM turnover is important in
the pathology of COPD.
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